Since the discovery of the platinum based complex, cisplatin, medicinal inorganic chemistry has attracted much more attention and a large number of platinum complexes with promising pharmacological properties have been synthesized. In this work a new platinum complex of N-(5-indanyl(methylene)anthranilic acid(5-indanyl methylene)-hydrazide (HL) has been synthesized and characterized by physical and spectral techniques, as elemental analysis, IR, EI-MS, 1 H-NMR, thermal analysis, transmittance electron microscope (TEM) and magnetic moment. The results indicated that the ligand binds to Pt(II) in the enol form. Square-planar stereochemistry was suggested for the Pt(II) complex. The morphological characterization showed nano-sized spherical particles with average size 92 nm of the isolated complex. The synthesized Pt(II) complex exhibited a significant cytotoxic activity against HCT116 and HEPG2. Also in vivo study of the Pt(II) complex showed cytotoxic activity towards Ehrlich ascites carcinoma (EAC).
INTRODUCTION
Cancer is the major serious problem which causes death all over the world. The cause of cancer is attributed to genetic damage to the cells. The damaged cells do not respond to normal tissue controls. The affected cells multiply rapidly to cause spread of cancer and formation of varying degrees of tumors [1] .
The discovery of effective new cancer therapies is a strong demand. Since the discovery of the platinum based complex, cisplatin, in 1965 [2] , medicinal inorganic chemistry has attracted much more attention and a large number of platinum complexes with promising pharmacological properties have been synthesized [3] . The cytotoxic action mechanism of many metal complexes has been discussed aiming to develop new anti-tumor agents [4, 5, 6, 7] . The presence of metal centers capable of binding to negatively charged bio-ligands, as proteins and nucleic acids offers the metal complexes excellent potential pharmaceutical properties [8, 9] . The metal complex is considered a chemotherapeutic agent in cancer treatment, when it slows and stops the cancer from spreading by killing the rapidly dividing cells. In chemotherapy, the target is to kill the tumor cells, without causing damage to the healthy cells. Cisplatin and carboplatin have been used in the treatment of various cancers as chemotherapeutic agents [3] . Serious side effects accompany the use of these drugs, so, trials are done to find new platinum complexes with less toxicity, to be used as potential anticancer agents [10] . As a result, new platinum complexes with different organic ligands have been designed [11, 12, 13, 14] .
In this paper a new Pt(II) complex of a hydrazide derivative N-(5-indanyl(methylene) anthranilic acid (5-indanyl methylene)-hydrazide has been synthesized and characterized by various techniques. The cytotoxic effect of the synthesized Pt(II) complex was studied.
To the best of our knowledge no work has been carried out on the present ligand, only a patent described the synthesis, the anti-inflammatory and analgesic activity of similar derivatives N-(substituted-naphthyl-1) anthranilic acid, was presented [15] .
MATERIALS AND METHODS
N-(5-indanyl(methylene)anthranilic acid(5-indanyl methylene)-hydrazide and PtCl 2 were purchased from Sigma-Aldrich (S512095).
1 H-NMR of the ligand in DMSO-d 6 δ (ppm): 2.0 (m, 2H, CH 3 ), 2.49 (t, 4H, C 5 -2H), 2.8 (t, 2H, 2H). CH=N appears at 6.8 (s, 1H), 7.43-7.8 (m, 10H).
Instruments
The elemental analysis, C, H and N were carried in the instrumentation center, Granada University, Spain 
Synthesis of Pt(II) Complex
0.001 M (0.265 gm) of PtCl 2 in 10 ml ethanol was injected to 0.001 M (0.40 gm) of (N-(5-indanyl(methylene)anthranilic acid (5-indanyl methylene)-hydrazide in 25 ml hot ethanolic solution under nitrogen. A yellow precipitate was formed on reflux. The reaction mixture was refluxed for 3 hrs and the precipitate was filtered off under vacuum.
The trials to obtain a single crystal from the platinum complex was failed. 
Pharmacological Testing
In vitro study (Cytotoxicity): Cytotoxic activity of Pt(II) was performed on a panel of human tumor cell line HEPG2 (hepatocellular carcinoma), HCT 116 (human colon cancer) at different concentrations. The method of Philp et al was used to carry out the cytotoxicity as sulphorhodamine-B(SRB) assay [17] . SRB is a protein stain in mild acidic conditions. This stain is used to provide a sensitive index of cellular protein content. It is a bright pink ammoxanthrene dye with two sulphonic groups.
In vivo study (Toxicity studies): LD50 of Pt(II) complex in mice was determined according to the method of Meier and Theakston [16] .
Dose response: Dose response of Pt(II) complex was determined in mice according to the method described by Crump et al [17] . Animal care and experiments were performed in accordance with NIH guide to the care and use of laboratory animals.
Experimental design: 20 female Swiss albino mice were divided into two groups (10 mice per each group): Group I is the positive control and injected intraperitonealy with 2.5x10 6 of Elhrlich ascites carcinoma "EAC" cells. Group II is the Pt(II) complex therapeutic group, injected intraperitonealy with 2.5x10 6 of Elhrlich ascites carcinoma "EAC" cells, and after one day of EAC injection, therapeutic group injected intaperitonealy with 5 mg/kg of Pt(II) complex day after day. At the end of the experiment, EAC cells were collected from mice and viability study was assayed.
Cell viability and counting of EAC cells:
Trypan blue exclusion method [18] was used to determine the counting and viability of EAC cells. The total and viable cells (nonstained) were determined in the two groups as the number of cells /ml at magnification power X40.
Statistical Analysis
SPSS software version 14 [19] was used to perform statistical analysis. One way analysis of variance was used to assess using the effect of each parameter. The results were presented as mean ± SD. Analysis of variance (ANOVA test), was used to determine the differences between mean values followed by Duncan's multiple rank test using MSTAT-C computer program. From linear regression analysis the statistical significance (where P≤ 0.05 was considered significant) of the relationships between variables was calculated.
RESULTS AND DISCUSSION

IR Spectra of the Ligand and Its Pt(II) Complex
Two tautomeric forms are suggested for the ligand, the Keto ( due to ν (NH). The strong bands at 1662 and 1621 cm -1 are attributed to ν (C=O) and ν (CONH), respectively [20, 21, 22, 23, 24] . These bands confirm the presence of the free ligand in the keto form. The ligand shows also, bands at 1605, 1306, 1199 and 971 cm -1 attributed to ν (HC=N), ν (C-O), ν (C-N) and ν (N-N), respectively [25, 26] .
Comparison of the IR spectrum of the ligand with that of Pt(II) complex reveals that the ligand chelates Pt(II) ion in a mono-negative bidentate mode via azomethine nitrogen (C=N) and the enolized carbonyl oxygen after displacement of hydrogen (Fig. 2) . The disappearance of the strong bands assigned to ν(NH), ν(CO) and ν(CONH) in the free ligand and the appearance of a new medium band at 1650 cm -1 assigned to ν (C=N * ) in the spectrum of Pt(II) complex support the suggested chelation mode. There is other possible coordination mode which may exist for the ligand, including formation of 5-membered chelate ring through N-N=CH group. This latter mode was discarded on the basis of the remaining of the bands at 969 and 1605 cm -1 due to ν (N-N) and ν (HC=N) unaltered in comparison with its position in the spectrum of the organic ligand. The remaining of these bands unaltered, confirms the inertness of N-* N active sites towards coordination [20] . The presence of hydrated water in the Pt(II) complex is confirmed by the presence of bands at 3431, 746 and 690 cm -1 due to  (OH),  (OH) and  w (OH), respectively [27, 28, 29] . New weak bands are observed at 557 and 449 cm -1 due to ν (M-O), ν (M-N) respectively [20] .
Pt(II) complex may exist either in N-N (cis), O-O(cis) or N-N(trans),O-O (trans).
Molecular mechanics method was used to predict rapidly the geometries of the two suggested conformers by using hyperchem series of programs [30] . The total energy calculations of the two structures indicated that the trans form is only 2 KJ mol -1 more stable than the cis form. 
1 H-NMR
Mass Spectra
The EI-MS of Pt(II) complex (Fig. 3) complex (Scheme 1). The molecular ion peak may lose four and half water molecules and the fragment [PtL] to give a peak at m/z = 406, assigned to the free ligand. The free ligand is fragmented by loss of propene and methane molecule by special rearrangement to give the peak at m/z = 346. The last peak is further fragmented by loss of carbon monoxide and nitrogen giving the base peak at m/z =304. The base peak loses hydrocyanic acid and nitrogen forming the peak at m/z = 263. In the second pathway, it was suggested that the molecular ion peak loses three and half molecules of water forming the peak at m/z = 1027. The latter peak is fragmented by lose of water molecule and the fragment C 6 H 3 giving the peak at m/z = 935. The latter peak loses tropyllium and furayl groups to give the peak at m/z = 778. The peak at m/z = 778 is further fragmented by loss of benzene and butadiene to give the peaks at m/z = 701 and 648, respectively. The last fragment loses butane to produce the fragment at m/z = 594, which loses hydrocyanic acid, carbon monoxide and nitrogen producing the fragment m/z = 525. The last fragment at m/z = 525 loses methane, ethylene and benzene leading to the peak corresponds to the free ligand at m/z = 407.
Magnetic Measurements
The Pt(II) complex is diamagnetic which confirms the formation of a square-planar stereochemistry around the Pt(II) ion [33]. 
Fig. 3. MS of Pt(II) complex
Thermal Analysis
TGA measurements of Pt(II) complex were carried out from 25˚C up to 1000˚C. The thermogram exhibits three events. The first resulted from the removal of water of hydration. This step starts from 25˚C to 140˚C [34] . The next step was attributed to the loss of two phenyl and four benzocyclopentane rings. This step takes place from 141˚C to 480˚C. (Found mass loss of this step is 55.5%, while the calculated mass loss is 57.0%). The last step starts from 461˚C to 880˚C, corresponding to the loss four hydrocyanic acid molecules (Found mass loss of this step is 8.7%; Calcd 9.0%). (Where, Z, h and K are the pre-exponential factor, Plank and Boltzmann constants, respectively [28] . The thermodynamic parameters were calculated for the second step, which is suitable for kinetic analysis, where there is no overlapping with other steps. The positive enthalpy and free energy values reveal the endothermic and non-spontaneous decomposition of this step, respectively. The negative entropy value indicates that the structure of the activated complex is more ordered than the reactants [29] .
Morphological Characterization
The chemical and biological activities of metal complexes were related to their particles size and shape [36, 37] . Transmittance electron microscope (TEM) was used to determine the particles shape and size of Pt(II) complex. From the TEM images (Fig. 4) , it is clear that the particles of Pt(II) complex are spherical in shape.
The possible formation mechanism of the spherical particles of Pt(Indanyl) complex has been proposed as indicated in Scheme 1. Under reflux conditions, the soluble Pt 2+ cation reacts with the indanyl ligand to form insoluble Pt(Indanyl) nucleus. In the first stage, Pt(Indanyl) complex follows a heterogeneous nucleation, where the energy barrier is lower than nucleation in solution [38, 39] . Initially, large numbers of small primary nanoparticles are formed. These primary particles have high surface energy, which makes them unstable. They aggregate rapidly and grow forming spherical nanoparticles. The nanospheres are assembled to each other via random attachment to reduce the surface energy forming thermodynamically stable structure. Finally, spontaneous aggregation takes place in spherical form to minimize the surface area.
Biological Study
Cytotoxicity: The in vitro cytotoxic activities of Pt(II) and the standard doxorubcin were shown in Table 2 and Figs 5, 6. The minimum inhibitory concentration of the synthesized compound was found to be 5.3 µg/ml and 9.68 µg/ml against HCT116 and HEPG2 cell lines, respectively. The colorimetric cytotoxicity tests showed that the Pt(II) complex has in vitro cytotoxic activity against the examined cancerous cell lines with IC 50 values of 9.08 µM and 5.43 µM against HCT116 and HEPG2 cell lines, respectively. The current results revealed that the present Pt complex inhibits cell proliferation in the same range as cisplatin and oxaliplatin.
Determination of median lethal dose (LD50) of Pt(II) complex:
The results revealed that, dose up to 100 mg/kg body weight was considered safe, where no mortality was observed. Table 3 summarizes the effect of Pt(II) complex on EAC cells volume and count. 
CONC(mg/ml). SURVIVING FRACTION
The results indicate mean volume of EAC of the positive control group is 3.9 ml. This value was significantly decreased by 42.5% in Pt(II) complex treated group (P< 0.05). Also, it was found that the mean count of EAC cells in the positive control group is 55.4x10 6 which was significantly decreased in Pt(II) complex treated group, compared to the positive control group. 
CONCLUSION
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